Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ALIM |
---|---|---|
10:06 ET | 100 | 3.92 |
10:28 ET | 100 | 3.92 |
10:39 ET | 1100 | 3.87 |
10:46 ET | 1500 | 3.865 |
11:08 ET | 200 | 3.77 |
11:09 ET | 14500 | 3.78 |
11:11 ET | 3300 | 3.81 |
11:13 ET | 200 | 3.83 |
11:15 ET | 100 | 3.86 |
11:18 ET | 100 | 3.89 |
11:20 ET | 16423 | 3.85 |
11:31 ET | 200 | 3.88 |
11:36 ET | 100 | 3.89 |
11:42 ET | 912 | 3.89 |
11:58 ET | 100 | 3.89 |
12:09 ET | 200 | 3.89 |
12:20 ET | 200 | 3.9 |
12:41 ET | 200 | 3.94 |
12:43 ET | 400 | 3.94 |
12:45 ET | 100 | 4.005 |
12:50 ET | 1900 | 3.925 |
01:12 ET | 200 | 3.915 |
01:37 ET | 100 | 3.955 |
01:39 ET | 500 | 3.8613 |
01:48 ET | 2454 | 3.9512 |
01:57 ET | 100 | 3.96 |
02:27 ET | 200 | 3.97 |
02:29 ET | 321 | 4.01 |
02:49 ET | 100 | 4.01 |
03:09 ET | 100 | 4.01 |
03:23 ET | 100 | 3.96 |
03:27 ET | 2577 | 3.95 |
03:39 ET | 100 | 3.9 |
03:41 ET | 200 | 3.945 |
03:52 ET | 100 | 3.88 |
03:54 ET | 400 | 3.91 |
03:57 ET | 100 | 3.95 |
03:59 ET | 207 | 3.9 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Alimera Sciences Inc | 204.2M | -1.8x | --- |
G1 Therapeutics Inc | 225.5M | -4.5x | --- |
Chromadex Corp | 262.1M | -52.8x | --- |
Codexis Inc | 245.4M | -3.1x | --- |
Innate Pharma SA | 191.3M | -31.7x | --- |
Personalis Inc | 75.3M | -0.7x | --- |
Alimera Sciences, Inc. is a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic retinal pharmaceuticals. It is engaged in developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a cause of blindness, and outside the United States for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. ILUVIEN is an intravitreal implant that treats patients by delivering a continuous micro dose of the corticosteroid fluocinolone acetonide (FAc) in the eye, for up to 36 months. ILUVIEN is inserted into the back of the patient's eye in a non-surgical procedure employing a device with a 25-gauge needle, which allows for a self-sealing wound. DME is also treated by laser photocoagulation, a retinal procedure in which a laser is used to apply a burn.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $204.2M |
---|---|
Revenue (TTM) | $80.8M |
Shares Outstanding | 52.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.18 |
EPS | $-2.16 |
Book Value | $0.88 |
P/E Ratio | -1.8x |
Price/Sales (TTM) | 2.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -3.73% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.